Table 3 In vitro antimicrobial activity of ceftazidime–avibactam and comparators against Pseudomonas aeruginosa isolates collected in the Asia–Pacific region (INFORM program, 2015–2017)

Pseudomonas aeruginosa (N = 2032)

 Amikacin

4

8

≤ 0.25–≥ 64

 Amoxicillin–clavulanic acid^a

≥ 64

≥ 64

0.5–≥ 64

N/A

N/A

 Aztreonam

8

32

≤ 0.015–≥ 256

 Cefepime

4

≥ 32

≤ 0.12–≥ 32

 Ceftazidime

2

64

0.06–≥ 256

 Ceftazidime–avibactam

2

8

≤ 0.015–≥ 256

 Colistin

1

2

≤ 0.06–8

 Imipenem

2

≥ 16

0.12–≥ 16

 Levofloxacin

0.5

≥ 16

0.008–≥ 16

 Meropenem

0.5

≥ 16

0.008–≥ 16

 Piperacillin–tazobactam

8

≥ 256

≤ 0.25–≥ 256

 Tigecycline^a

8

≥ 16

≤ 0.015–≥ 16

N/A

N/A

P. aeruginosa, MDR (N = 475)

 Amikacin

4

≥ 64

≤ 0.25–≥ 64

71.6

21.5

 Amoxicillin–clavulanic acid^a

≥ 64

≥ 64

32–≥ 64

N/A

N/A

 Aztreonam

32

128

0.25–≥ 256

25.9

74.1

 Cefepime

16

≥ 32

1–≥ 32

26.3

73.7

 Ceftazidime

64

≥ 256

0.5–≥ 256

20.2

79.8

 Ceftazidime–avibactam

8

128

0.25–≥ 256

68.6

31.4

 Colistin

1

2

0.12–2

100

0.0

 Imipenem

≥ 16

≥ 16

0.25–≥ 16

41.1

58.9

 Levofloxacin

8

≥ 16

0.06–≥ 16

25.1

74.9

 Meropenem

8

≥ 16

0.12–≥ 16

38.3

43.8

 Piperacillin–tazobactam

128

≥ 256

≤ 0.25–≥ 256

5.1

94.9

 Tigecycline^a

≥ 16

≥ 16

0.03–≥ 16

N/A

N/A

P. aeruginosa, carbapenemase-positive, MBL-positive (N = 76)

 Amikacin

32

≥ 64

2–≥ 64

10.5

76.3

 Amoxicillin–clavulanic acid^a

≥ 64

≥ 64

≥ 64–≥ 64

N/A

N/A

 Aztreonam

16

≥ 256

0.25–≥ 256

52.6

47.4

 Cefepime

≥ 32

≥ 32

16–≥ 32

0.0

100

 Ceftazidime

128

≥ 256

16–≥ 256

0.0

100

 Ceftazidime–avibactam

128

≥ 256

2–≥ 256

3.9

96.1

 Colistin

1

1

0.5–2

100

0.0

 Imipenem

≥ 16

≥ 16

4–≥ 16

1.3

98.7

 Levofloxacin

≥ 16

≥ 16

0.5–≥ 16

3.9

96.1

 Meropenem

≥ 16

≥ 16

8–≥ 16

0.0

96.1

 Piperacillin–tazobactam

128

≥ 256

8–≥ 256

6.6

93.4

 Tigecycline^a

≥ 16

≥ 16

4–≥ 16

N/A

N/A